文献速递前列腺癌

达罗他胺与安慰剂的安全性特征:系统综述与Meta分析

Safety profile of darolutamide versus placebo: a systematic review and meta-analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2023-12-14

该系统综述与Meta分析纳入3项临床试验共2902例前列腺癌患者(达罗他胺1652例,安慰剂1250例),比较达罗他胺与安慰剂的安全性。达罗他胺未增加导致治疗终止的不良事件(汇总OR 1.176,95%CI 0.918-1.507,p=0.633),但骨骨折风险显著高于安慰剂(汇总OR 1.523,95%CI 1.081-2.146)。作者认为在缺乏不同雄激素受体通路抑制剂头对头比较研究的情况下,结果提示在已批准适应症中可优先考虑达罗他胺。

要点

  • 达罗他胺与安慰剂相比未增加导致治疗终止的不良事件(汇总OR 1.176,95%CI 0.918-1.507)。
  • 骨骨折是唯一在达罗他胺与安慰剂间有统计学差异的关注不良事件,有利于安慰剂(汇总OR 1.523,95%CI 1.081-2.146)。
  • 作者认为在缺乏头对头比较研究时,结果提示在已批准适应症中可优先考虑达罗他胺。

核心结论

  • 在以安慰剂为对照的系统综述与Meta分析中,达罗他胺的毒性特征与安慰剂相当,但骨骨折除外。
  • 作者认为,在缺乏不同雄激素受体通路抑制剂头对头比较研究的情况下,本研究结果提示在已批准适应症中可优先使用达罗他胺。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed/Medline和Cochrane图书馆数据库,纳入所有以安慰剂为对照评估达罗他胺治疗前列腺癌的临床试验。
  • 共纳入3篇文章、2902例患者,其中达罗他胺组1652例,安慰剂组1250例。
  • 以比值比(OR)作为Meta分析效应量,比较达罗他胺与安慰剂的安全性和耐受性。

主要发现

  • 达罗他胺与安慰剂相比未增加导致治疗终止的不良事件(汇总OR 1.176,95%CI 0.918-1.507,p=0.633)。
  • 在乏力、心律失常、心脏疾病、冠状动脉疾病、抑郁情绪障碍、跌倒、疲乏、心力衰竭、潮热、高血压、精神障碍、皮疹、癫痫发作和体重减轻方面,达罗他胺与安慰剂之间无差异。
  • 骨骨折是唯一在达罗他胺与安慰剂之间有统计学显著差异的关注不良事件,有利于安慰剂(汇总OR 1.523,95%CI 1.081-2.146)。

局限性

  • 作者指出,目前缺乏不同雄激素受体通路抑制剂之间的头对头比较研究。
  • 作者在结论中基于上述缺乏头对头比较研究的情况,认为结果提示在已批准适应症中可优先使用达罗他胺。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Darolutamide is an androgen receptor pathway inhibitor (ARPI) used in patients with prostate cancer (PC). In pivotal trials, it has demonstrated a favorable toxicity profile. There are no head-to-head comparison studies between the different ARPIs, but the efficacy of these drugs seems to be similar making the toxicity profile a key element for treatment selection. METHODS: We conducted a systematic review of all clinical trials assessing treatment with darolutamide for patients with PC using placebo as the control using the PubMed/Medline and Cochrane library databases. We also performed a meta-analysis to compare the safety of darolutamide versus placebo evaluating adverse events (AE) leading to treatment discontinuation and the rate of the AE reported as "AE of interest" in the ARAMIS trial. The comparison among darolutamide and the placebo group in terms of safety and tolerability was performed using odds ratio (OR) as meta-analytic outcome. RESULTS: We identified three articles comprising 2902 patients for the systematic review and meta-analysis (1652 treated with darolutamide and 1250 with placebo). Darolutamide did not increase AE leading to treatment discontinuation compared to placebo (pooled OR: 1.176, 95% CI 0.918-1.507, p = 0.633). Regarding the "AE of interest" there was no difference between darolutamide and placebo in terms of asthenia, cardiac arrhythmia, cardiac disorder, coronary artery disorder, depression mood disorder, falls, fatigue, heart failure, hot flushes, hypertension, mental-impairment disorder, rash, seizure and weight loss. The only "AE of interest" with a statistically significant difference in favor of placebo was bone fractures (pooled OR: 1.523, 95% CI 1.081-2.146). CONCLUSIONS: In our systematic review and meta-analysis, darolutamide showed a toxicity profile comparable to placebo with the exception of bone fractures. In the absence of head-to-head comparison studies between the different ARPIs, the results of our research suggest a preferred use of darolutamide in the approved settings.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Turco F, Gillessen S, Treglia G, et al. Safety profile of darolutamide versus placebo: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2023. PMID: 38097723. doi:10.1038/s41391-023-00775-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。